🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Sajid Khan

Abdul Wali Khan University Mardan

ORCID: 0000-0003-1331-8846
Materials ScienceBiochemistry, Genetics and Molecular BiologyMedicinePhysics and Astronomy

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 15 papers. Top paper: “Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity”.

Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity

Nature Communications(2020)10.1038/s41467-020-15838-0
N/A
0.838DataRank · unranked
266 citations

Xuan Zhang, Jianhui Chang, Ha‐Neui Kim, Peiyi Zhang, Yingying Wang +17 more

DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas

Journal of Hematology & Oncology(2020)10.1186/s13045-020-00928-9
N/A
0.739DataRank · unranked
137 citations

Raphael Koch, Vivekananda Budamagunta, Peiyi Zhang, Xuan Zhang, Sajid Khan +11 more

BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers

Journal of Hematology & Oncology(2022)10.1186/s13045-022-01241-3
N/A
0.621DataRank · unranked
62 citations

J Wiegand, Peiyi Zhang, Wanyi Hu, Dinesh Thummuri, Vivekananda Budamagunta +9 more

PROTAC-mediated dual degradation of BCL-xL and BCL-2 is a highly effective therapeutic strategy in small-cell lung cancer

bioRxiv (Cold Spring Harbor Laboratory)(2024)10.1101/2024.02.27.582353
N/A
0.312DataRank · unranked
7 citations

Lin Cao, J Wiegand, Peiyi Zhang, Maria Zajac‐Kaye, Frederic J. Kaye +3 more

Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity,

Nature Communications(2021)10.1038/s41467-021-27210-x
N/A
0DataRank · unranked
149 citations

Pratik Pal, Xingui Liu, Yannan Jia, Dinesh Thummuri, Peiyi Zhang +19 more

Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL–Specific Degrader DT2216

Molecular Cancer Therapeutics(2021)10.1158/1535-7163.mct-21-0474
N/A
0DataRank · unranked
74 citations

Sajid Khan, Patrick W. Underwood, Peiyi Zhang, J Wiegand, Xuan Zhang +13 more

Proteolysis-targeting chimera against BCL-XL destroys tumor-infiltrating regulatory T cells

Nature Communications(2021)10.1038/s41467-021-21573-x
N/A
0DataRank · unranked
55 citations

Umasankar De, Sajid Khan, Yuewan Luo, Myung‐Chul Kim, Haijun Yu +14 more

Co-targeting BCL-X L and MCL-1 with DT2216 and AZD8055 synergistically inhibits small-cell lung cancer growth without causing on-target toxicities in mice

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.09.12.507616
N/A
0DataRank · unranked
0 citations

Patrick Kellish, Nick Connis, Dinesh Thummuri, J Wiegand, Peiyi Zhang +14 more

Co-targeting BCL-XL and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice

Cell Death Discovery(2023)10.1038/s41420-022-01296-8
N/A
0DataRank · unranked
43 citations

Patrick Kellish, Nick Connis, Dinesh Thummuri, J Wiegand, Peiyi Zhang +14 more

Targeting KRAS in pancreatic cancer: Emerging therapeutic strategies

Advances in cancer research(2023)10.1016/bs.acr.2023.02.004
N/A
0DataRank · unranked
19 citations

Vivekananda Budamagunta, Daohong Zhou, Sajid Khan

PROTAC-Mediated Dual Degradation of BCL-xL and BCL-2 Is a Highly Effective Therapeutic Strategy in Small-Cell Lung Cancer

Cells(2024)10.3390/cells13060528
N/A
0DataRank · unranked
29 citations

Lin Cao, J Wiegand, Peiyi Zhang, Maria Zajac‐Kaye, Frederic J. Kaye +3 more

Discovery of PZ671, a highly potent and in vivo active CRBN-recruiting Bcl-xL degrader

RSC Medicinal Chemistry(2025)10.1039/d5md00119f
N/A
0DataRank · unranked
3 citations

Dinesh Thummuri, Wanyi Hu, Sajid Khan, Yonghan He, Xuan Zhang +5 more

Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies

Journal of Hematology & Oncology(2020)10.1186/s13045-020-00924-z
N/A
0DataRank · unranked
123 citations

Sajid Khan, Zhiguang Huo, Dongwen Lv, Xuan Zhang, Xingui Liu +6 more

Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity

European Journal of Medicinal Chemistry(2020)10.1016/j.ejmech.2020.112186
N/A
0DataRank · unranked
115 citations

Dinesh Thummuri, Xingui Liu, Wanyi Hu, Peiyi Zhang, Sajid Khan +4 more

PROTACs are effective in addressing the platelet toxicity associated with BCL-XL inhibitors

Exploration of Targeted Anti-tumor Therapy(2020)10.37349/etat.2020.00017
N/A
0DataRank · unranked
23 citations

Xuan Zhang, Xingui Liu, Sajid Khan, Daohong Zhou, Guangrong Zheng +1 more